Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Расстройства сна в клинической практике
Расстройства сна в клинической практике
Ляшенко Е.А., Левин О.С. Расстройства сна в клинической практике. Справочник поликлинического врача. 2017; 4: 57–61.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Расстройства сна относятся к одним из наиболее частых нарушений в клинической практике. Как инсомния, так и гиперсомния могут носить первичный характер или бывают связаны с тем или иным неврологическим или соматическим заболеванием. Нарушения сна приводят к снижению работоспособности, хронической усталости, злоупотреблению снотворными препаратами, частым дорожно-транспортным происшествиям, повышают риск развития психических расстройств. В статье расстройства сна рассматриваются с позиций Международной классификации расстройств сна 3-го пересмотра. Приведены рекомендации по медикаментозному и немедикаментозному лечению нарушений сна.
Ключевые слова: сон, расстройства сна, инсомния, гиперсомния, парасомния, снотворные.
Key words: sleep, sleep disorders, insomnia, hypersomnia, parasomnia, hypnotics.
Ключевые слова: сон, расстройства сна, инсомния, гиперсомния, парасомния, снотворные.
________________________________________________
Key words: sleep, sleep disorders, insomnia, hypersomnia, parasomnia, hypnotics.
Полный текст
Список литературы
1. Михайлова Н.М. Нарушения сна в пожилом и старческом возрасте. Клинические рекомендации по лечению. Рус. мед. журн. 2003; 28. / Mikhailova N.M. Narusheniia sna v pozhilom i starcheskom vozraste. Klinicheskie rekomendatsii po lecheniiu. Rus. med. zhurn. 2003; 28. [in Russian]
2. Полуэктов М.Г., Левин Я.И. Инсомния. Сомнология и медицина сна. Избранные лекции. Под ред. Я.И.Левина, М.Г.Полуэктова. М.: Медфорум-альфа, 2013; с. 192–220. / Poluektov M.G., Levin Ia.I. Insomniia. Somnologiia i meditsina sna. Izbrannye lektsii. Pod red. Ia.I.Levina, M.G.Poluektova. M.: Medforum-alfa, 2013; s. 192–220. [in Russian]
3. Соколова Л.П., Кислый Н.Д. Нарушения сна у пожилых: особенности терапии. Consilium Medicum. 2007; 9 (2): 133–7. / Sokolova L.P., Kislyi N.D. Narusheniia sna u pozhilykh: osobennosti terapii. Consilium Medicum. 2007; 9 (2): 133–7. [in Russian]
4. Ancoli-Israel S, Ayalon L. Diagnosis and treatment of sleep disorders in older adults. Am J Geriatr Psychiatry 2006; 14: 95–103.
5. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomnias. Arch Gerontol Geriatr 1997; 24 (2): 223–31.
6. Grossman E, Ludon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vask Health Risk Manag 2011; 7: 577–84.
7. Iranzo A, Fernández-Arcos A, Tolosa E et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014; 26. 9 (2): e89741.
8. Kripke DF, Garfinkel L, Wingard DL et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002; 59 (2): 131–6.
9. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009; 24 (5): 239–49.
10. Morin CM, LeBlanc M, Daley M et al. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006; 7 (2): 123–30. Epub 2006 Feb 3.
11. Otmani S, Demazieres A, Staner C et al. Effect of prolonged-release melatonin, zolpidem, and their combination on psychomotццц22or functions, memory recall, and driving skills in healthy middle aged and elderlu volunteers. Hum Psychopharmacol 2008; 23 (8): 693–705.
12. Paul MA, Gray G, MacLellan M, Pigeau RA. Sleep-inducing pharmaceuticals: a comporison of melatonin, zaleplon, zopiclon and temazepam. Aviat, Space Environ Med 2004; 75 (6): 512–9.
13. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007; 3 (Suppl. 5): S7–10.
14. Schadeck B, Chelly M, Amsellem D et al. Comparative efficacy of doxylamine and zolpidem for the treatment of common insomnia. Sep Hop Paris 1996; 72 (13–14): 428–39.
15. Sharma M, Palacios-Bois J, Schwartz G et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989; 25 (3): 305–19.
16. Stone KL, Ewing SK, Ancoli-Israel S et al. Self-reported sleep and nap habits and risk of mortality in a large cohort of older women. J Am Geriatr Soc 2009; 57: 604–11.
17. Wade AG, Ford I, Crawford G et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007; 23 (10): 2597–605.
2. Poluektov M.G., Levin Ia.I. Insomniia. Somnologiia i meditsina sna. Izbrannye lektsii. Pod red. Ia.I.Levina, M.G.Poluektova. M.: Medforum-alfa, 2013; s. 192–220. [in Russian]
3. Sokolova L.P., Kislyi N.D. Narusheniia sna u pozhilykh: osobennosti terapii. Consilium Medicum. 2007; 9 (2): 133–7. [in Russian]
4. Ancoli-Israel S, Ayalon L. Diagnosis and treatment of sleep disorders in older adults. Am J Geriatr Psychiatry 2006; 14: 95–103.
5. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomnias. Arch Gerontol Geriatr 1997; 24 (2): 223–31.
6. Grossman E, Ludon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vask Health Risk Manag 2011; 7: 577–84.
7. Iranzo A, Fernández-Arcos A, Tolosa E et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014; 26. 9 (2): e89741.
8. Kripke DF, Garfinkel L, Wingard DL et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002; 59 (2): 131–6.
9. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009; 24 (5): 239–49.
10. Morin CM, LeBlanc M, Daley M et al. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006; 7 (2): 123–30. Epub 2006 Feb 3.
11. Otmani S, Demazieres A, Staner C et al. Effect of prolonged-release melatonin, zolpidem, and their combination on psychomotццц22or functions, memory recall, and driving skills in healthy middle aged and elderlu volunteers. Hum Psychopharmacol 2008; 23 (8): 693–705.
12. Paul MA, Gray G, MacLellan M, Pigeau RA. Sleep-inducing pharmaceuticals: a comporison of melatonin, zaleplon, zopiclon and temazepam. Aviat, Space Environ Med 2004; 75 (6): 512–9.
13. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007; 3 (Suppl. 5): S7–10.
14. Schadeck B, Chelly M, Amsellem D et al. Comparative efficacy of doxylamine and zolpidem for the treatment of common insomnia. Sep Hop Paris 1996; 72 (13–14): 428–39.
15. Sharma M, Palacios-Bois J, Schwartz G et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989; 25 (3): 305–19.
16. Stone KL, Ewing SK, Ancoli-Israel S et al. Self-reported sleep and nap habits and risk of mortality in a large cohort of older women. J Am Geriatr Soc 2009; 57: 604–11.
17. Wade AG, Ford I, Crawford G et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007; 23 (10): 2597–605.
2. Полуэктов М.Г., Левин Я.И. Инсомния. Сомнология и медицина сна. Избранные лекции. Под ред. Я.И.Левина, М.Г.Полуэктова. М.: Медфорум-альфа, 2013; с. 192–220. / Poluektov M.G., Levin Ia.I. Insomniia. Somnologiia i meditsina sna. Izbrannye lektsii. Pod red. Ia.I.Levina, M.G.Poluektova. M.: Medforum-alfa, 2013; s. 192–220. [in Russian]
3. Соколова Л.П., Кислый Н.Д. Нарушения сна у пожилых: особенности терапии. Consilium Medicum. 2007; 9 (2): 133–7. / Sokolova L.P., Kislyi N.D. Narusheniia sna u pozhilykh: osobennosti terapii. Consilium Medicum. 2007; 9 (2): 133–7. [in Russian]
4. Ancoli-Israel S, Ayalon L. Diagnosis and treatment of sleep disorders in older adults. Am J Geriatr Psychiatry 2006; 14: 95–103.
5. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomnias. Arch Gerontol Geriatr 1997; 24 (2): 223–31.
6. Grossman E, Ludon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vask Health Risk Manag 2011; 7: 577–84.
7. Iranzo A, Fernández-Arcos A, Tolosa E et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014; 26. 9 (2): e89741.
8. Kripke DF, Garfinkel L, Wingard DL et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002; 59 (2): 131–6.
9. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009; 24 (5): 239–49.
10. Morin CM, LeBlanc M, Daley M et al. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006; 7 (2): 123–30. Epub 2006 Feb 3.
11. Otmani S, Demazieres A, Staner C et al. Effect of prolonged-release melatonin, zolpidem, and their combination on psychomotццц22or functions, memory recall, and driving skills in healthy middle aged and elderlu volunteers. Hum Psychopharmacol 2008; 23 (8): 693–705.
12. Paul MA, Gray G, MacLellan M, Pigeau RA. Sleep-inducing pharmaceuticals: a comporison of melatonin, zaleplon, zopiclon and temazepam. Aviat, Space Environ Med 2004; 75 (6): 512–9.
13. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007; 3 (Suppl. 5): S7–10.
14. Schadeck B, Chelly M, Amsellem D et al. Comparative efficacy of doxylamine and zolpidem for the treatment of common insomnia. Sep Hop Paris 1996; 72 (13–14): 428–39.
15. Sharma M, Palacios-Bois J, Schwartz G et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989; 25 (3): 305–19.
16. Stone KL, Ewing SK, Ancoli-Israel S et al. Self-reported sleep and nap habits and risk of mortality in a large cohort of older women. J Am Geriatr Soc 2009; 57: 604–11.
17. Wade AG, Ford I, Crawford G et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007; 23 (10): 2597–605.
________________________________________________
2. Poluektov M.G., Levin Ia.I. Insomniia. Somnologiia i meditsina sna. Izbrannye lektsii. Pod red. Ia.I.Levina, M.G.Poluektova. M.: Medforum-alfa, 2013; s. 192–220. [in Russian]
3. Sokolova L.P., Kislyi N.D. Narusheniia sna u pozhilykh: osobennosti terapii. Consilium Medicum. 2007; 9 (2): 133–7. [in Russian]
4. Ancoli-Israel S, Ayalon L. Diagnosis and treatment of sleep disorders in older adults. Am J Geriatr Psychiatry 2006; 14: 95–103.
5. Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomnias. Arch Gerontol Geriatr 1997; 24 (2): 223–31.
6. Grossman E, Ludon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vask Health Risk Manag 2011; 7: 577–84.
7. Iranzo A, Fernández-Arcos A, Tolosa E et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014; 26. 9 (2): e89741.
8. Kripke DF, Garfinkel L, Wingard DL et al. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002; 59 (2): 131–6.
9. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009; 24 (5): 239–49.
10. Morin CM, LeBlanc M, Daley M et al. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006; 7 (2): 123–30. Epub 2006 Feb 3.
11. Otmani S, Demazieres A, Staner C et al. Effect of prolonged-release melatonin, zolpidem, and their combination on psychomotццц22or functions, memory recall, and driving skills in healthy middle aged and elderlu volunteers. Hum Psychopharmacol 2008; 23 (8): 693–705.
12. Paul MA, Gray G, MacLellan M, Pigeau RA. Sleep-inducing pharmaceuticals: a comporison of melatonin, zaleplon, zopiclon and temazepam. Aviat, Space Environ Med 2004; 75 (6): 512–9.
13. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007; 3 (Suppl. 5): S7–10.
14. Schadeck B, Chelly M, Amsellem D et al. Comparative efficacy of doxylamine and zolpidem for the treatment of common insomnia. Sep Hop Paris 1996; 72 (13–14): 428–39.
15. Sharma M, Palacios-Bois J, Schwartz G et al. Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989; 25 (3): 305–19.
16. Stone KL, Ewing SK, Ancoli-Israel S et al. Self-reported sleep and nap habits and risk of mortality in a large cohort of older women. J Am Geriatr Soc 2009; 57: 604–11.
17. Wade AG, Ford I, Crawford G et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007; 23 (10): 2597–605.
Авторы
Е.А.Ляшенко, О.С.Левин*
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*oslevin@mail.ru
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*oslevin@mail.ru
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*oslevin@mail.ru
________________________________________________
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*oslevin@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.